Geistlich Pharma AG
Geistlich Pharma AG, a leading name in the regenerative medicine sector, is headquartered in Switzerland (CH) and operates extensively across Europe and North America. Founded in 1851, the company has established itself as a pioneer in dental and orthopaedic biomaterials, focusing on innovative solutions for tissue regeneration. With a strong emphasis on research and development, Geistlich Pharma offers a range of unique products, including collagen-based membranes and bone substitutes, which are renowned for their quality and efficacy. The company’s commitment to scientific excellence has positioned it as a trusted partner in the healthcare industry, achieving notable milestones in clinical applications and product advancements. Geistlich Pharma AG continues to set benchmarks in regenerative medicine, enhancing patient outcomes worldwide.
DitchCarbon Score
How does Geistlich Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Geistlich Pharma AG's score of 26 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Geistlich Pharma AG's reported carbon emissions
Geistlich Pharma AG, headquartered in Switzerland (CH), currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. In the absence of specific emissions data, it is important to note that many companies in the pharmaceutical industry are increasingly focusing on sustainability and climate commitments. This often includes setting science-based targets for reducing greenhouse gas emissions across various scopes, including Scope 1 (direct emissions), Scope 2 (indirect emissions from energy), and Scope 3 (indirect emissions from the supply chain). As the industry evolves, Geistlich Pharma AG may consider establishing measurable climate commitments to align with global sustainability goals and enhance its environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Geistlich Pharma AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
